Jiangsu Recbio Technology (2179 HK)

Jiangsu Recbio Technology is an innovative vaccine company dedicated to the research, development, production, and commercialization of recombinant protein vaccines and related adjuvant technologies. Its pipeline includes vaccines for cervical cancer, shingles, COVID-19, influenza, and tuberculosis. The company was founded in 2012 and is headquartered in Taizhou, Jiangsu, PRC.